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Background: Recombinant human platelet-derived growth factor (rhPDGF) is safe and effective for
the treatment of periodontal defects in short-term studies up to 6 months in duration. We now provide
results from a 36-month extension study of a multicenter, randomized, controlled clinical trial evaluating
the effect and long-term stability of PDGF-BB treatment in patients with localized severe periodontal os-
seous defects.
Methods: A total of 135 participants were enrolled from six clinical centers for an extension trial. Eighty-
three individuals completed the study at 36 months and were included in the analysis. The study investi-
gated the local application of b-tricalcium phosphate scaffold matrix with or without two different dose
levels of PDGF (0.3 or 1.0 mg/mL PDGF-BB) in patients possessing one localized periodontal osseous
defect. Composite analysis for clinical and radiographic evidence of treatment success was defined as
percentage of cases with clinical attachment level (CAL) ‡2.7 mm and linear bone growth (LBG) ‡1.1 mm.
Results: The participants exceeding this composite outcome benchmark in the 0.3 mg/mL rhPDGF-BB
group went from 62.2% at 12 months, 75.9% at 24 months, to 87.0% at 36 months compared with 39.5%,
48.3%, and 53.8%, respectively, in the scaffold control group at these same time points (P <0.05). Although
there were no significant increases in CAL and LBG at 36 months among all groups, there were continued
increases in CAL gain, LBG, and percentage bone fill over time, suggesting overall stability of the regener-
ative response.
Conclusion: PDGF-BB in a synthetic scaffoldmatrix promotes long-term stable clinical and radiographic
improvements as measured by composite outcomes for CAL gain and LBG for patients possessing
localized periodontal defects (ClinicalTrials.gov no. CT01530126). J Periodontol 2013;84:456-464.
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P
latelet-derived growth factor (PDGF) is a
thoroughly studied growth factor in clinical
periodontics for the treatment of localized
periodontal osseous and soft tissue defects.1-3 Since
PDGF was first discovered to promote the regener-
ation of bone, cementum, and periodontal ligament
(PDL),4 nearly 100 investigations have been pub-
lished on its effect on PDL and alveolar bone and on
the regeneration of the periodontium preclinically
and clinically.5-9 A number of studies have clearly
demonstrated the presence of cell surface receptors
for PDGF on PDL and alveolar bone cells and elu-
cidated the stimulatory effect of PDGFs on the
proliferation and chemotaxis of these cells.10,11 Re-
combinant human PDGF (rhPDGF-BB) promotes
the regeneration of periodontal tissue, including
bone, cementum, and PDL in vivo.6,12-17 A clinical
trial studying the application of 0.15 mg/mL
rhPDGF-BB and 0.15 mg/mL recombinant human
insulin-like growth factor I to local periodontal defects
resulted in a significant improvement in bone fill
compared with conventional surgery plus a vehicle
control.18 Furthermore, rhPDGF-BB (becaplermin)
has been clinically available for >10 years for the
treatment of chronic neuropathic and diabetic cuta-
neous ulcers.19,20
A proof-of-principal case series demonstrated the
capability of satisfying the definition of periodontal
regeneration for both infrabony and Class II furcation
defects. The treatment used rhPDGF with a matrix of
bone allograft with the biopsy harvest of the tooth,
and supporting periodontium after 6 months showed
clear evidence of the stimulation of new bone, ce-
mentum, and PDL.21
The growth-factor-enhanced matrix system is a
fully synthetic bone regeneration system composed
of a purified recombinant PDGF§§ and a synthetic
calcium phosphate matrix.9ii This combination ther-
apy has received Food and Drug Administration
(FDA) clearance for its use in the treatment of osseous
defects, to act physically as a filler and provide a
biocompatible, osteoconductive, three-dimensional
matrix to facilitate new bone formation.22 The original
clinical trial from which this long-term evaluation
was derived evaluated the application of the matrix
with buffer alone and buffer containing one of two
concentrations, 0.3 or 1.0 mg/mL rhPDGF-BB. This
pivotal trial enrolled 180 patients with infrabony de-
fects, 77% of which included a component of 1- and
2-wall morphologies.9 The 6-month follow-up eval-
uation demonstrated that the use of rhPDGF-BB was
safe and effective in the treatment of periodontal os-
seous defects. A similar study was recently published
by an independent research team who corroborated
the findings in a randomized clinical trial of 54 human
participants (Clinicaltrials.gov no. NCT00496847).7
To evaluate the long-term stability of the improved
radiographic and clinical parameters resulting from
the use of scaffold + rhPDGF-BB, an extension study
to the pivotal clinical trial was performed. Endpoints
included changes in clinical attachment level (CAL),
probing depth (PD), linear bone growth (LBG), per-
centage bone fill (%BF), and composite outcome of
bone and CAL with evaluations at 12, 24, and 36
months from a subset of six of the original 11 centers
that participated in the pivotal trial.
MATERIALS AND METHODS
This long-term study was an extension of the pivotal
trial by Nevins et al.9 and included clinical and ra-
diographic evaluations at 12, 24, and 36 months after
implantation of the study device (Fig. 1A). All par-
ticipants provided written informed consent in ac-
cordance with the Institutional Review Board of each
participating center. The pivotal study was conducted
at 11 centers, enrolling a total of 180 participants with
advanced periodontal defects (Fig. 1B). The initial
study population was randomized into three treatment
groups of 60 participants each: 1) b-tricalcium
phosphate (b-TCP) (scaffold) with sodium acetate
buffer alone; 2) b-TCP with sodium acetate buffer
containing 0.3 mg/mL rhPDGF-BB; and 3) b-TCP
with sodium acetate buffer containing 1.0 mg/mL
rhPDGF-BB.
All participants who completed the treatment and
follow-up phases (visits 1 through 13) were eligible
for entry into the extension study. Postoperative visits
were scheduled for the extension period (visits 14
through 17) from a total of six of the 11 centers in-
volved in pivotal trial (the centers of WVG, JEH, RTK,
BSM, PKM, and MKM).9 Centers withdrew from the
study principally because patients returned to their
primary dentist for maintenance care.
The effectiveness measures consisted of CAL gain,
PD reduction (PDR), gingival recession (GR), radio-
graphic LBG, and radiographic %BF, as described
previously.9 Additional analyses were performed,
comparing the percentage of participants (test
treatments compared to active control) meeting
combined historical benchmarks of effectiveness
for CAL gain and radiographic LBG and CAL gain
and radiographic %BF to determine the percentage
of participants having a successful outcome at 12,
24, and 36 months after treatment from 2001 to
2006.23
The expected duration of participant involvement
in the extended study was 36 months after implan-
tation of the study device. Study follow-up visits,
including clinical and radiographic evaluation, rep-
resent the standard of care for participants receiving
§§ BioMimetric Therapeutics, Franklin, TN.
ii Gem 21S, Osteohealth, Shirley, NY.
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Figure 1.
A) Study timeline of the extension investigation. Patientswere randomized at baseline and followedupat3, 6, 12, 24, and36monthsafter surgeryand device
delivery. BD = bone depth; W = width; GR = gingival recession; Sx = surgery. B) Patient disposition Consolidated Standards of Reporting Trials (CONSORT)
flow diagram of patients from initial entry and 6, 12, 24, and 36 months after therapy.
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regular dental care and provided
nothing in addition to what is
provided in routine patient man-
agement care.
Participants were discontinued
from the study if 1) the partici-
pant requested to be withdrawn
from the study or 2) the prin-
cipal investigator decided that
it was in the participant’s best
interest to discontinue partici-
pation in the study (e.g., more
efficient for patient to go to
general dentist for maintenance
care). Five of the original study
centers decided not to partici-
pate in the extension study.
An Internet-based remote data
entry system¶¶ was used to
collect clinical trial data at the
investigational sites.Thesystem
complied with FDA Title 21
Code of Federal Regulations
Part II and was used to enter,
modify, maintain, archive, re-
trieve, and transmit data. The
study was conducted in accor-
dance with good clinical practice
(GCP) standards in that all col-
lected data were supported by
complete and thorough source
documentation as verified by
the study monitors.
An interexaminer quality assur-
ance procedure was conducted
using a masked periodontist to
independently evaluate the ra-
diographs and identify poten-
tial discrepancies of ‡20% in
bone fill for reassessment by
the radiologic technician. The
potential discrepancies were
queried by the periodontist con-
ducting the review and were
reassessed and verified or cor-
rected by the radiographic tech-
nician and the study director.
Corrections and revisions were
documented in conformance with
GCPs.
Effectiveness data were ex-




PDGF promotes periodontal bone repair. A patient with a localized bony defect as initially described in the
original study cohort9 is shown. The baseline defect (A), the 1-year reentry (B), the baseline radiograph
(C), the 3-year postoperative radiograph (D), and the 10-year postoperative radiograph (E) and clinical
photograph (F), demonstrating periodontal repair and stability of the result.
Figure 3.
PDGF promotes periodontal wound repair. A localized osseous defect (A) has PDGF-BB delivered to the
defect in the scaffold matrix (B). Radiographs at baseline (C) and 3 years postoperative (D).
¶¶ Target e*CRF, Target Health, New York,
NY.
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displayed as counts and percentages, and continu-
ous variables were displayed as means, medians,
standard deviations, and ranges. Statistical compar-
isons between the test product treatment groups
(0.3 and 1.0 mg/mL PDGF in carrier) and the scaffold
alone were made using x2 or Fisher exact test for
categorical variables and t tests or analysis of vari-
ance methods (ANOVA) for continuous variables. In
addition, an analysis of covariance model included
the baseline covariates of defect class, and current
smoking status was applied to control for covariates
when estimating the treatment effect.
Comparisons among treatment groups for ordinal
variables were made using Cochran-Mantel-Haenszel
methods. P £0.05 (one-sided) was considered to be
statistically significant for CAL, LBG, and %BF.
Composite endpoint analyses used literature refer-
ence means to identify historical benchmarks of ef-
fectiveness for change in CAL
(2.7 mm) and LBG (1.1 mm)
as described previously.23 An
additional survivor analysis
was performed to show that the
baseline data from the survivor
population of the extension
study is representative of the
results from the population of
the original study cohort at
baseline.9 The study was de-
signed and powered for the
6-month endpoint, and, given
that there was a reduction in
study centers for the extension
study, there was a reduction in
statistical power. ‘‘Survivors’’
are defined as those participants
from the original 6-month
study that participated in the
12-, 24-, and/or 36-month ex-
tension study. The smoking
status and defect classification
at baseline, clinical (CAL gain,
PDR, and GR change) and ra-
diographic (LBG and %BF) as-
sessments at 6 months were
examined for the 12-, 24-, and
36-month survivors and non-
survivors. The statistical com-
parisons for these assess-
ments, between survivors and
non-survivors, at the three time
points (12, 24, and 36 months)
were made using a x2 test for
the categorical measurements
and ANOVA for the continuous
measurements.
RESULTS
A survivor analysis was performed to establish that
participants involved in the 12-, 24-, and 36-month
extension study (‘‘survivors’’) for each treatment
group were not statistically significantly different
from the participants not participating in the extension
study (‘‘non-survivors’’) with regard to baseline defect
characteristics and participant demographics, as well
as 6-month clinical and radiographic results. Overall,
there were no statistically significant differences ob-
served among the survivor and non-survivor pop-
ulations for all parameters tested at baseline (except
for defect characteristics at the coronal portion of the
lesions for the 36-month population), confirming the
ability to evaluate for changes in clinical and radio-
graphic parameters at 12, 24, and 36 months from
baseline and the original 6-month conclusion of the
Figure 4.
PDGF delivery promotes CAL gain, PDR, and bone gain. A) PDR over time among groups. B) CAL gain.
C) %BF. D) LBG. n = 83 to 178 participants per group (for details, see Fig. 1B). Bars show mean – SD.
*P <0.001 for scaffold vs. 0.3 mg/mL rhPDGF-BB; †P = 0.019, ‡P <0.007, §P = 0.022, kP = 0.021,
¶P = 0.008 for scaffold vs. 1.0 mg/mL rhPDGF-BB.
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trial. Some examples of cases treated in the trial for ‡3
years are shown in Figures 2 and 3.
The clinical improvements observed 6 months
after surgery for both rhPDGF-BB treatment groups
persisted throughout the 12-, 24-, and 36-month
visits and are shown in Figure 4. Similarly to the
original report, the 0.3 mg/mL rhPDGF-BB + scaffold
group showed the greatest improvement in CAL gain
and PDR throughout the 36-month study (Fig. 4).
The 0.3 mg/mL rhPDGF-BB + scaffold treatment
demonstrated a statistically significant increase from
baseline compared with treatment with scaffold alone
in radiographic LBG (mm) and radiographic %BF
in participants at the 12-month (LBG, 2.88 versus
1.42; %BF, 60.5 versus 32.6; P £0.001) and the
24-month (LBG, 3.32 versus 1.81; %BF, 68.3 versus
41.5;P £0.001)postoperative visits. The1.0mg/mL
rhPDGF-BB + scaffold treatment also demonstrated
a statistically significant increase in LBG and %BF
from baseline compared with the scaffold control
(LBG, 2.25 versus 1.42, P = 0.008; %BF, 53.7 versus
32.6, P <0.007) in participants who completed the
12-month postoperative visit and in %BF (57.3 ver-
sus 41.5, P = 0.022) in participants who completed
the 24-month postoperative visit. These improve-
ments persisted throughout the 36-month follow-up
period, although they were not significant. At the
6-month postoperative visit, both the 0.3 mg/mL
rhPDGF-BB + scaffold and 1.0 mg/mL rhPDGF-BB
treatment demonstrated a statistically significant in-
crease in LBG and improvement in %BF compared with
the control (P £0.001).
To assess the cumulative
beneficial effect for clinical and
radiographic outcomes, a com-
posite analysis was performed
to determine the percentage of
participants with a successful
outcome as defined by CAL
‡2.7 mm and LBG ‡1.1 mm
or by CAL ‡2.7 mm and %BF
‡14.1% at 12, 24, and 36
months (Fig. 5).
At the 12-month post-
operative visit, 62.2% of the
0.3 mg/mL rhPDGF-BB group
and 60.5% of the 1.0 mg/mL
rhPDGF-BB group exceeded
the composite benchmark for
success compared to 39.5% of
the scaffold group, resulting in
a statistically significant benefit
in CAL ‡2.7 mm and LBG ‡1.1
mm (P = 0.017 and 0.026, re-
spectively). For the composite
analysis of CAL and %BF, the
only difference was at 12 months for the 1.0 mg/mL
dose of PDGF versus the scaffold (P <0.05).
At the 24-month postoperative visit, 75.9% of the
0.3 mg/mL rhPDGF-BB group exceeded the compo-
site benchmark for success compared with 48.3% of
scaffold group participants, resulting in a statistically
significant benefit in CAL ‡2.7 mm and LBG ‡1.1 mm
(P = 0.015). The results of the 3-year long-term ex-
tension study demonstrate statistically significant
composite CAL and LBGbenefits for both rhPDGF-BB
treatment groups (0.3 and 1.0 mg/mL rhPDGF-BB +
scaffold) compared with scaffold alone based on his-
torical benchmarks of effectiveness.
The influence of smoking and defect type are shown
in Figure 6. It was noted that the greatest responses
in LBG and %BF were for defects treated with 0.3
mg/mL PDGF in the scaffold matrix (data not shown
for the 1.0 mg/mL PDGF-BB dose). However, these
differences were not significant at the 12-, 24-, and
36-month time points for all of the clinical measures
when comparing the 0.3 mg/mL PDGF dose to matrix
alone or matrix plus 1.0 mg/mL PDGF (Figs. 2 through
4). For 1- to 2-wall defects versus 3-wall/circum-
ferential defects, all groups demonstrated increases
over time, but no differences were shown when the
defects were stratified in this manner by 36 months
(Fig. 6).
DISCUSSION
The optimal goal of periodontal treatment regimens is
to restore periodontal health and to retain the result
over a significant time frame. Periodontal regeneration
Figure 5.
Composite outcome analysis of CALand LBG shows 0.3mg/mL PDGF stimulates periodontal regeneration.
A) The percentage of participants demonstrating CAL > 2.7 mm and LBG > 1.1 mm. B) Composite
outcome of CAL and %BF. *P = 0.017 for scaffold vs. 0.3 mg/mL rhPDGF-BB; †P <0.03 for scaffold vs.
1.0 mg/mL PDGF-BB; ‡P = 0.015, §P = 0.006 for scaffold vs. 0.3 mg/mL PDGF-BB.
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is defined as providing new cementum, new bone,
and a new PDL on a tooth surface previously exposed
to disease.24 This should improve the prognosis of
the tooth by making the area amenable to patient
and therapist debridement procedures. Over the past
years, there have been significant interest and en-
couraging outcomes in the development of growth
factor–based therapies to stimulate periodontal re-
generation,25,26 with the recent publication of sev-
eral important randomized controlled clinical trials
and case series using growth factors, such as PDGF-
BB,7,27 fibroblast growth factor-2,28 and growth and
differentiation-5.29 These trials highlight the contin-
ued investigation of the field of growth factor biology
and bioengineering technologies to promote re-
generation of periodontal osseous defects. As such, it
is important to extend these studies to the long term
to identify how well these regenerative strategies
support long-term success. Furthermore, when com-
paring these findings to more well-studied regen-
erative biomaterials as summarized in meta-analyses
of guided tissue regener-
ation30,31 and enamel matrix
derivative,32 these results com-
pare favorably for CAL gain,
bone height, and bone fill
in short-term and long-term
trials.33
The use of 0.3 mg/mL
rhPDGF-BB + scaffold for
the treatment of periodontal
osseous defects resulted in the
greatest CAL gain and PDR,
with significantly greater in-
creases in radiographic LBG
and %BF from baseline com-
pared with sites treated with
scaffold alone through 24
months. At 36 months, the ef-
fect was sustained but no longer
statistically significant, which
may have been attributable to
the lessened power because
the original power calculation
was performed on the 6-month
endpoint for FDA clearance.9
The clinical significance of
these results is further con-
firmed by comparison to his-
torical controls.
Descriptive subgroup anal-
yses (no P values) were per-
formed to determine baseline
characteristic trends that could
influence effectiveness out-
comes (data not shown). The
radiographic LBG and %BF measurements at the
6-, 12-, 24-, and 36-month postoperative follow-up
visits, for participants who completed the entire fol-
low-up continuation study, by smoking status, bone
defect depth, and defect class overall, showed limited
differences as a result of stratifications of the overall
small sample sizes per group (27 to 28 participants
per group) (Fig. 1B). The trends demonstrated
overall lessened responses in effectiveness attribut-
able to smoking on the effectiveness for all therapies,
consistent with the impact of smoking on regeneration
and the cellular response.34,35 Of interest, it appeared
that there was an enhanced effect of PDGF on pro-
moting healing in smokers compared with non-
smokers. It is not clear as to thismechanism, but it has
been noted that activation of nicotine receptors via
smoking leads to increased transcription and ex-
pression of PDGF-b receptors (the most responsive
receptors to PDGF protein).36 As such, there could
be a process that allows this heightened response, but
this result should be interpreted with caution given the
Figure 6.
Effect of smoking (A andB) and defect type (C andD) on LBG (A and C) and %BF (B and D). Bars show
mean– SD (for details, see Fig. 1B).*P<0.001 for scaffold vs. 0.3mg/mL rhPDGF-BB;†P<0.03 for scaffold
vs. 1.0 mg/mL PDGF-BB (data not shown).
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small sample size. In addition, the influence of bony
defect type on the regenerative outcomes was also in
alignment with other studies on regeneration, sug-
gesting a greater impact on regeneration with a greater
number of bony walls.37 Although not significant, the
trend still favored the addition of PDGF at the 0.3-
mg/mL dose on the regenerative response compared
with scaffold alone or scaffold + 1.0 mg/mL PDGF
(Fig. 6). In both this study and the initial report at 6
months, 0.3 mg/mL PDGF is favored over the 1.0-
mg/mL dose. The reasons are not completely clear,
but it is likely that there is a feedback regulation of
receptor expression because of the very high dosing
of PDGF locally.11
rhPDGF-BB at 0.3 mg/mL is a bone regeneration
system comprising a wound-healing agent and a
biocompatible, osteoconductive, three-dimensional
scaffold (b-TCP). This extension study report is
based on 12-, 24-, and 36-month postoperative data
available for clinical and radiographic measure-
ments as summarized below.
rhPDGF-BB at 0.3 mg/mL was found to be an
effective treatment for the restoration of soft tissue
attachment level and bone as shown by the follow-
ing: 1) a consistent improvement in CAL gain from
baseline through 6, 12, 24, and 36 months after
treatment; 2) significantly improved radiographic
LBG and %BF compared with the scaffold control, be-
tween baseline and 6, 12, 24, and 36 months after
treatment; and 3) significantly improved composite
outcomes, combining hard- and soft- tissue measure-
ments based on historical benchmarks of effectiveness
(CAL and LBG) compared with the scaffold control.
CONCLUSION
rhPDGF-BB at 0.3 mg/mL was shown to result in
significantly greater composite clinical and radio-
graphic improvements, from baseline throughout the
36-month observation period, in moderate-to-severe
2- and 3-wall periodontal infrabony defects.
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